2022 - Research.com Immunology in United Kingdom Leader Award
2020 - Distinguished Fellows of the American Association of Immunologists (AAI)
2014 - Canada Gairdner International Award
2010 - Member of the National Academy of Sciences
2008 - Dr. Paul Janssen Award for Biomedical Research, Johnson & Johnson for their role in the discovery of tumor necrosis factor-alpha, or TNF-alpha, as an effective therapeutic target for rheumatoid arthritis and other autoimmune diseases.
2006 - Fellow of the Royal Society, United Kingdom
Member of the Association of American Physicians
Member of the European Molecular Biology Organization (EMBO)
Marc Feldmann spends much of his time researching Immunology, Tumor necrosis factor alpha, Rheumatoid arthritis, Cytokine and Arthritis. Immunology is a component of his Pathogenesis, Antigen, Antibody, Immune system and Monoclonal antibody studies. His studies examine the connections between Tumor necrosis factor alpha and genetics, as well as such issues in Receptor, with regards to Extracellular.
Marc Feldmann usually deals with Rheumatoid arthritis and limits it to topics linked to Autoimmunity and Human leukocyte antigen. His Cytokine research integrates issues from Proinflammatory cytokine, Inflammation, Synovial membrane and Autoimmune disease. His studies deal with areas such as Alpha and Ex vivo as well as Arthritis.
Marc Feldmann mainly investigates Immunology, Tumor necrosis factor alpha, Antigen, Cytokine and Rheumatoid arthritis. His Immunology study frequently draws connections to adjacent fields such as Receptor. His Tumor necrosis factor alpha study integrates concerns from other disciplines, such as Cancer research, Clinical trial, Blockade, Necrosis and Pharmacology.
His biological study spans a wide range of topics, including In vitro, T cell, Antigen-presenting cell, Molecular biology and Cell biology. His work deals with themes such as Proinflammatory cytokine, Endocrinology and Synovial membrane, which intersect with Cytokine. Autoimmune disease is closely connected to Autoimmunity in his research, which is encompassed under the umbrella topic of Rheumatoid arthritis.
Marc Feldmann mostly deals with Immunology, Tumor necrosis factor alpha, Inflammation, Rheumatoid arthritis and Cytokine. His Immunology study combines topics in areas such as Receptor and Internal medicine. His studies in Internal medicine integrate themes in fields like Gastroenterology and Endocrinology.
His work carried out in the field of Tumor necrosis factor alpha brings together such families of science as Cancer research, Necrosis, Postoperative cognitive dysfunction, Neuroinflammation and Fibrosis. His research on Rheumatoid arthritis also deals with topics like
The scientist’s investigation covers issues in Immunology, Tumor necrosis factor alpha, Inflammation, Cytokine and Arthritis. The study of Immunology is intertwined with the study of Receptor in a number of ways. His Tumor necrosis factor alpha research includes themes of NFKB1, Neuroinflammation, Cellular infiltration and Postoperative cognitive dysfunction.
His Inflammation study incorporates themes from Signal transduction, Cell type and Pneumonia. His study in Cytokine is interdisciplinary in nature, drawing from both Blockade, Antibody and FOXP3. His Arthritis research incorporates themes from Porphyromonas gingivalis, IRF5 and Transcription factor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
P E Lipsky;D M van der Heijde;E W St Clair;D E Furst.
The New England Journal of Medicine (2000)
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
R Maini;E W St Clair;F Breedveld;D Furst.
The Lancet (1999)
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Marc Feldmann;Fionula M. Brennan;Ravinder N. Maini.
Annual Review of Immunology (1996)
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
M.J Elliott;R.N Maini;M Feldmann;J.R Kalden.
The Lancet (1994)
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Ravinder N. Maini;Ferdinand C. Breedveld;Joachim R. Kalden;Josef S. Smolen.
Arthritis & Rheumatism (1998)
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Marc Feldmann;Ravinder N. Maini.
Annual Review of Immunology (2001)
ROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY
G F Bottazzo;R Pujol-Borrell;T Hanafusa;M Feldmann.
The Lancet (1983)
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
Richard O. Williams;Marc Feldmann;Ravinder N. Maini.
Proceedings of the National Academy of Sciences of the United States of America (1992)
IRF5 Promotes Inflammatory Macrophage Polarization and TH1-TH17 Responses
Thomas Krausgruber;Katrina Blazek;Timothy Smallie;Saba Alzabin.
Nature Immunology (2011)
Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.
F M Brennan;D Chantry;A Jackson;R Maini.
The Lancet (1989)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Imperial College London
Imperial College London
Imperial College London
University of Oxford
Gadeta (Netherlands)
University of Oxford
University of Oxford
Academy of Athens
University of Oxford
University of Washington
University of Modena and Reggio Emilia
Mitsubishi Electric (United States)
Facebook (United States)
Chinese Academy of Sciences
University of Manchester
National Institutes of Health
National Oceanic and Atmospheric Administration
University of Cambridge
Vanderbilt University Medical Center
University of Colorado Boulder
German Sport University Cologne
The Ohio State University
Temple University
Stony Brook University
Oulu University Hospital
Columbia University